Perflubron as a gastrointestinal MR imaging contrast agent in the pediatric population

G. S. Bisset, K. H. Emery, M. P. Meza, N. K. Rollins, S. Don, J. S. Shorr

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective. To evaluate the safety and efficacy of orally administered perflubron for bowel recognition on MR imaging in a pediatric population. Materials and methods. A multicenter trial evaluated 39 pediatric subjects before and after ingestion of perflubron with T1-, proton-density, and T2-weighted sequences through the abdomen and/or pelvis. Post-contrast images were compared with pre-contrast images. Safety was evaluated through assessment of adverse events, clinical laboratory parameters, and vital signs. Results. With regard to efficacy analysis, improvement in the percent of bowel darkened was observed for 85% of the subjects on T1-weighted images and for 95% of the subjects on proton-density and T2-weighted images. For images of the abdominal region, the percent of bowel darkened was improved for 90-92% of the subjects across pulse sequences. Improvement rates for the images of the pelvic region ranged from 71% to 100%. For at least 75% of the subjects, proton-density and T2-weighted images of the body and tail of the pancreas, left lobe of the liver, mesenteric fat, and pathological tissue were improved relative to predosing images. Twenty-three percent of the subjects experienced some adverse effects, most of which were minor and related to the digestive system. Clinical laboratory and vital sign evaluations revealed no trends associated with the administration of perflubron. Conclusion. Perflubron is a relatively safe and effective gastrointestinal MR contrast agent in the pediatric population.

Original languageEnglish (US)
Pages (from-to)409-415
Number of pages7
JournalPediatric Radiology
Volume26
Issue number6
DOIs
StatePublished - 1996

Fingerprint

Contrast Media
Pediatrics
Protons
Vital Signs
Pelvis
Population
Safety
Digestive System
Body Image
Abdomen
Multicenter Studies
Pancreas
Eating
Fats
perflubron
Liver

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Pediatrics, Perinatology, and Child Health
  • Radiological and Ultrasound Technology

Cite this

Perflubron as a gastrointestinal MR imaging contrast agent in the pediatric population. / Bisset, G. S.; Emery, K. H.; Meza, M. P.; Rollins, N. K.; Don, S.; Shorr, J. S.

In: Pediatric Radiology, Vol. 26, No. 6, 1996, p. 409-415.

Research output: Contribution to journalArticle

Bisset, G. S. ; Emery, K. H. ; Meza, M. P. ; Rollins, N. K. ; Don, S. ; Shorr, J. S. / Perflubron as a gastrointestinal MR imaging contrast agent in the pediatric population. In: Pediatric Radiology. 1996 ; Vol. 26, No. 6. pp. 409-415.
@article{eef8189bac0c4cb9ae059a90ec345b58,
title = "Perflubron as a gastrointestinal MR imaging contrast agent in the pediatric population",
abstract = "Objective. To evaluate the safety and efficacy of orally administered perflubron for bowel recognition on MR imaging in a pediatric population. Materials and methods. A multicenter trial evaluated 39 pediatric subjects before and after ingestion of perflubron with T1-, proton-density, and T2-weighted sequences through the abdomen and/or pelvis. Post-contrast images were compared with pre-contrast images. Safety was evaluated through assessment of adverse events, clinical laboratory parameters, and vital signs. Results. With regard to efficacy analysis, improvement in the percent of bowel darkened was observed for 85{\%} of the subjects on T1-weighted images and for 95{\%} of the subjects on proton-density and T2-weighted images. For images of the abdominal region, the percent of bowel darkened was improved for 90-92{\%} of the subjects across pulse sequences. Improvement rates for the images of the pelvic region ranged from 71{\%} to 100{\%}. For at least 75{\%} of the subjects, proton-density and T2-weighted images of the body and tail of the pancreas, left lobe of the liver, mesenteric fat, and pathological tissue were improved relative to predosing images. Twenty-three percent of the subjects experienced some adverse effects, most of which were minor and related to the digestive system. Clinical laboratory and vital sign evaluations revealed no trends associated with the administration of perflubron. Conclusion. Perflubron is a relatively safe and effective gastrointestinal MR contrast agent in the pediatric population.",
author = "Bisset, {G. S.} and Emery, {K. H.} and Meza, {M. P.} and Rollins, {N. K.} and S. Don and Shorr, {J. S.}",
year = "1996",
doi = "10.1007/BF01387316",
language = "English (US)",
volume = "26",
pages = "409--415",
journal = "Pediatric Radiology",
issn = "0301-0449",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Perflubron as a gastrointestinal MR imaging contrast agent in the pediatric population

AU - Bisset, G. S.

AU - Emery, K. H.

AU - Meza, M. P.

AU - Rollins, N. K.

AU - Don, S.

AU - Shorr, J. S.

PY - 1996

Y1 - 1996

N2 - Objective. To evaluate the safety and efficacy of orally administered perflubron for bowel recognition on MR imaging in a pediatric population. Materials and methods. A multicenter trial evaluated 39 pediatric subjects before and after ingestion of perflubron with T1-, proton-density, and T2-weighted sequences through the abdomen and/or pelvis. Post-contrast images were compared with pre-contrast images. Safety was evaluated through assessment of adverse events, clinical laboratory parameters, and vital signs. Results. With regard to efficacy analysis, improvement in the percent of bowel darkened was observed for 85% of the subjects on T1-weighted images and for 95% of the subjects on proton-density and T2-weighted images. For images of the abdominal region, the percent of bowel darkened was improved for 90-92% of the subjects across pulse sequences. Improvement rates for the images of the pelvic region ranged from 71% to 100%. For at least 75% of the subjects, proton-density and T2-weighted images of the body and tail of the pancreas, left lobe of the liver, mesenteric fat, and pathological tissue were improved relative to predosing images. Twenty-three percent of the subjects experienced some adverse effects, most of which were minor and related to the digestive system. Clinical laboratory and vital sign evaluations revealed no trends associated with the administration of perflubron. Conclusion. Perflubron is a relatively safe and effective gastrointestinal MR contrast agent in the pediatric population.

AB - Objective. To evaluate the safety and efficacy of orally administered perflubron for bowel recognition on MR imaging in a pediatric population. Materials and methods. A multicenter trial evaluated 39 pediatric subjects before and after ingestion of perflubron with T1-, proton-density, and T2-weighted sequences through the abdomen and/or pelvis. Post-contrast images were compared with pre-contrast images. Safety was evaluated through assessment of adverse events, clinical laboratory parameters, and vital signs. Results. With regard to efficacy analysis, improvement in the percent of bowel darkened was observed for 85% of the subjects on T1-weighted images and for 95% of the subjects on proton-density and T2-weighted images. For images of the abdominal region, the percent of bowel darkened was improved for 90-92% of the subjects across pulse sequences. Improvement rates for the images of the pelvic region ranged from 71% to 100%. For at least 75% of the subjects, proton-density and T2-weighted images of the body and tail of the pancreas, left lobe of the liver, mesenteric fat, and pathological tissue were improved relative to predosing images. Twenty-three percent of the subjects experienced some adverse effects, most of which were minor and related to the digestive system. Clinical laboratory and vital sign evaluations revealed no trends associated with the administration of perflubron. Conclusion. Perflubron is a relatively safe and effective gastrointestinal MR contrast agent in the pediatric population.

UR - http://www.scopus.com/inward/record.url?scp=0029893065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029893065&partnerID=8YFLogxK

U2 - 10.1007/BF01387316

DO - 10.1007/BF01387316

M3 - Article

VL - 26

SP - 409

EP - 415

JO - Pediatric Radiology

JF - Pediatric Radiology

SN - 0301-0449

IS - 6

ER -